Clinical ResultsIV GTx-104 has demonstrated bioequivalence to oral nimodipine, and the prospective, open-label, randomized Phase III STRIVE-ON safety study demonstrated numerically less clinically significant hypotension.
Market OpportunityGTx-104 represents a $300MM+ opportunity, with potential upside following real-world experience given KOL enthusiasm.
Product DevelopmentGTx-104 will be a welcome alternative treatment for aneurysmal subarachnoid hemorrhage.